These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 26839521)
1. The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices. Konety B; Zappala SM; Parekh DJ; Osterhout D; Schock J; Chudler RM; Oldford GM; Kernen KM; Hafron J Rev Urol; 2015; 17(4):231-40. PubMed ID: 26839521 [TBL] [Abstract][Full Text] [Related]
2. Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. Punnen S; Pavan N; Parekh DJ Rev Urol; 2015; 17(1):3-13. PubMed ID: 26028995 [TBL] [Abstract][Full Text] [Related]
3. The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information. Zappala SM; Dong Y; Linder V; Reeve M; Sjoberg DD; Mathur V; Roberts R; Okrongly D; Newmark J; Sant G; Steiner M Int J Clin Pract; 2017 Jun; 71(6):. PubMed ID: 28497893 [TBL] [Abstract][Full Text] [Related]
4. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698 [TBL] [Abstract][Full Text] [Related]
5. The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer. Maccini MA; Westfall NJ; Van Bokhoven A; Lucia MS; Poage W; Maroni PD; Wilson SS; Glodé LM; Arangua P; Newmark J; Steiner M; Werahera PN; Crawford ED Prostate; 2018 May; 78(7):506-511. PubMed ID: 29460452 [TBL] [Abstract][Full Text] [Related]
6. Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: Overall cost savings and improved quality of care to the us healthcare system. Voigt JD; Dong Y; Linder V; Zappala S Rev Urol; 2017; 19(1):1-10. PubMed ID: 28522924 [TBL] [Abstract][Full Text] [Related]
7. Implementation of 4Kscore as a Secondary Test Before Prostate Biopsy: Impact on US Population Trends for Prostate Cancer. Scuderi S; Tin A; Gandaglia G; Stabile A; Montorsi F; Briganti A; Vickers AJ Eur Urol Open Sci; 2023 Jun; 52():1-3. PubMed ID: 37182119 [TBL] [Abstract][Full Text] [Related]
8. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients. Dell'Atti L J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458 [TBL] [Abstract][Full Text] [Related]
9. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial. Josefsson A; Månsson M; Kohestani K; Spyratou V; Wallström J; Hellström M; Lilja H; Vickers A; Carlsson SV; Godtman R; Hugosson J Eur Urol; 2024 Sep; 86(3):223-229. PubMed ID: 38772787 [TBL] [Abstract][Full Text] [Related]
10. Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort. Lonergan PE; Vertosick EA; Assel M; Sjoberg DD; Haese A; Graefen M; Boorjian SA; Klee GG; Cooperberg MR; Pettersson K; Routila E; Vickers AJ; Lilja H BJU Int; 2021 Aug; 128(2):218-224. PubMed ID: 33306251 [TBL] [Abstract][Full Text] [Related]
11. Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer. Punnen S; Nahar B; Soodana-Prakash N; Koru-Sengul T; Stoyanova R; Pollack A; Kava B; Gonzalgo ML; Ritch CR; Parekh DJ PLoS One; 2018; 13(8):e0201384. PubMed ID: 30092002 [TBL] [Abstract][Full Text] [Related]
12. Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine. Fredsøe J; Rasmussen M; Tin AL; Vickers AJ; Borre M; Sørensen KD; Lilja H Sci Rep; 2022 Sep; 12(1):15193. PubMed ID: 36071094 [TBL] [Abstract][Full Text] [Related]
13. The 4Kscore Predicts the Grade and Stage of Prostate Cancer in the Radical Prostatectomy Specimen: Results from a Multi-institutional Prospective Trial. Punnen S; Nahar B; Prakash NS; Sjoberg DD; Zappala SM; Parekh DJ Eur Urol Focus; 2017 Feb; 3(1):94-99. PubMed ID: 28720374 [TBL] [Abstract][Full Text] [Related]
14. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination. Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560 [TBL] [Abstract][Full Text] [Related]
15. Does free to total ratio of prostate-specific antigen alter decision-making on prostatic biopsy? Alivizatos G; Deliveliotis C; Mitropoulos D; Raptides G; Louras G; Karayiannis A; Becopoulos T; Dimopoulos AM Urology; 1996 Dec; 48(6A Suppl):71-5. PubMed ID: 8973704 [TBL] [Abstract][Full Text] [Related]
16. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Littrup PJ; Kane RA; Mettlin CJ; Murphy GP; Lee F; Toi A; Badalament R; Babaian R Cancer; 1994 Dec; 74(12):3146-58. PubMed ID: 7526969 [TBL] [Abstract][Full Text] [Related]
17. Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results. Zappala SM; Scardino PT; Okrongly D; Linder V; Dong Y Rev Urol; 2017; 19(3):149-155. PubMed ID: 29302237 [TBL] [Abstract][Full Text] [Related]
18. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548 [TBL] [Abstract][Full Text] [Related]
19. Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Potter SR; Horniger W; Tinzl M; Bartsch G; Partin AW Urology; 2001 Jun; 57(6):1100-4. PubMed ID: 11377318 [TBL] [Abstract][Full Text] [Related]
20. Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer? Morote J; Celma A; Roche S; de Torres IM; Mast R; Semedey ME; Regis L; Planas J Eur Urol Oncol; 2019 Nov; 2(6):664-669. PubMed ID: 31411977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]